Background-The safety of high dose inhaled steroids has been a subject of debate. The efficacy and safety of beclomethasone dipropionate and budesonide inhalations were evaluated by measuring their effects on pulmonary function, on the hypothalamic-pituitaryadrenocortical axis, and on carbohydrate metabolism in adults with unstable asthma. Methods-Fifteen adults with unstable asthma and 15 healthy controls were studied. Eight patients were treated with beclomethasone dipropionate in initially high (2 mg/day for five months) and subsequently lower (1 mg/day for three months) doses. Seven patients were treated with budesonide at doses of 1-6 mg/day for five months followed by 0-8 mg/day for three months. Blood glucose and serum insulin were measured in an oral glucose tolerance test and plasma cortisol in an adrenocorticotrophic hormone test. The antiasthmatic effect of treatment was evaluated by measuring peak morning expiratory flow rates and forced expiratory volume in one second (FEVy).
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Results-The FEV, increased significantly after one month of treatment (medians 88% v 96%, p < 0.01), and nocturnal symptoms disappeared within two weeks of treatment in both groups. At one month, the high dose significantly decreased serum insulin concentrations as calculated from the areas under the incremental two hour curves in the glucose tolerance test. The Inhaled glucocorticoids are highly effective in the treatment of asthma and they are now recommended even in the early stages of newly detected disease.' The antiasthmatic effect of inhaled glucocorticoids is, however, associated with dose related systemic effects.2' Decreased insulin sensitivity, without significant effects on glucose tolerance or cortisol secretion, has been found in healthy adults inhaling beclomethasone (1 mg/day for one month)4 and in children with asthma inhaling budesonide (0O8 mglm2/day for one month). 5 The purpose of the present study was to evaluate the efficacy and safety of beclomethasone dipropionate and budesonide inhaled in high dosage during a longer treatment period. We report the effects on pulmonary function, on the hypothalamicpituitary-adrenocortical axis, and on carbohydrate metabolism in adults with unstable asthma.
Methods

SUBJECTS
Ten women and five men with asthma were studied. Their ages ranged from 18 to 56 (mean 33 7) years, and the duration of asth-Effect of of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma All the patients were admitted to hospital for a baseline period of three to seven days.
On the first hospital day, peak expiratory flow (PEF) was measured every six hours and thereafter in the morning and evening before and after inhaled /2 agonists. Diurnal variation of PEF ranged from 8% to 51% (median 25%).
The patients were randomised into two treatment groups: eight patients were treated with beclomethasone dipropionate and seven patients with budesonide. Table 1 presents the clinical characteristics of these groups. A glucose tolerance test was also performed on 15 healthy controls matched for age, sex, and body mass index (table 1) .
Informed consent was obtained from all patients. The study protocol was approved by the ethics committee of the department.
STUDY DESIGN Inhaled /32 agonists and oral theophylline were continued at the dosage already used. The daily dose varied from 0 4 to 0-8 mg for salbutamol (beclomethasone dipropionate group) and from 1 0 to 2 0 mg for terbutaline (budesonide group). Each patient was studied on four occasions: before treatment, and after one month, five months, and eight months of treatment. During the first treatmnent period of five months, eight patients were treated with beclomethasone dipropionate at a daily dose of 2 mg divided into morning and evening doses. Seven patients were treated with budesonide at a daily dose of 1-6 mg also divided into morning and evening doses. After five months of treatment the beclomethasone dipropionate dose was reduced to 1 mg/day and the budesonide dose to 0-8 mg/day divided into two doses for the next three months. Beclomethasone dipropionate and budesonide were inhaled from a metered dose inhaler with a "spacer" device (Volumatic, Glaxo, London, UK or Nebuhaler, Draco AB, Lund, Sweden). After inhalation the patients rinsed their mouths. The patients used a standard diary card to record symptoms of asthma and any additional use of /)2 agonists. The doses of /32 agonists had to be stable (the same dosage as at the baseline) during the seven days before the tests. At each examination, they were admitted to the ward at 8-00 am after a 10 hour overnight fast. All treatment was stopped for 12 hours before the tests.
ASSESSMENT
The blood samples for determination of blood glucose, glycosylated haemoglobin, plasma cortisol, and serum insulin were taken between 8-00 and 9 00 am. The patients were given 75 g glucose orally in a volume of 300 ml. Blood samples for glucose and insulin determinations were obtained 60 and 120 minutes after oral glucose. Thereafter 0-25 mg synthetic tetracosactide (S-Cortophin, NV, Organon, Oss, The Netherlands) Months of treatment. At 20 days the median PEF was 94% for beclomethasone dipropionate (p < 0-05) and 96% for budesonide (p < 0 05). After one month of treatment, the median FEVy as a percentage of the predicted value increased from 88% to 96% (p < 001) when both groups were analysed together. At five months the value was 96% (p < 0 05) and at eight months it was 92% (NS).
In both groups, nocturnal symptoms disappeared after two weeks of treatment, and no additional /3, agonist was needed apart from temporary use during acute respiratory infections. In all the patients, the dosage of /3, agonists had been at the baseline level, at least during the seven days before the tests. Table 2 shows the metabolic changes during treatment. No significant changes occurred in the fasting blood glucose concentrations. In both treatment groups the individual values were normal (<6.7 mmol/l).' The fasting serum insulin concentration did not change during treatment. Neither blood glucose nor serum insulin concentrations in the glucose tolerance test were significantly affected by beclomethasone dipropionate or budesonide. Impaired glucose tolerance (two hour blood glucose 6-7 to 10 mmolIl)" was found in one patient at baseline and at one and eight months. Blood glycosylated haemoglobin did not change significantly during treatment.
At one month, the area under the incremental two hour blood glucose curve decreased significantly (medians 1-4 v 0 4 mmoVlVh <005; fig 1) when both groups were analysed together. The five and eight month values were intermediate (medians 0-8 and 0-7 mmol/lIh, respectively). These changes were not significant when compared either with the baseline or with one month values.
In both treatment groups, the high dose significantly decreased the areas under the incremental two hour insulin curves at one month (fig 2) . The decrease was 59% for beclomethasone ( healthy adults inhaling 1 mg beclomethasone dipropionate a day for one month4 and in children with asthma inhaling 0-8 mg/M2 budesonide a day for one month.5 The discrepancy between these studies and the present results might be explained by the difference in the selection of subjects. Our patients were stressed by the disease and had higher insulin concentrations at the baseline than healthy adults4 or children with asthma.5 Thus the changes in insulin sensitivity seem more likely to depend on the stress caused by uncontrolled asthma than on a systemic effect of glucocorticoids.
In conclusion, high doses of inhaled beclomethasone dipropionate and budesonide produced a rapid antiasthmatic effect in adults with unstable asthma. Decreased sensitivity to insulin was found in these patients before treatment with glucocorticoids. The antiasthmatic effect was accompanied by a significant early decrease in insulin resistance with a parallel improvement in glucose tolerance. During prolonged treatment a slight decrease in insulin sensitivity was found. These findings suggest that the overall effect of beclomethasone dipropionate and budesonide inhalations on carbohydrate metabolism is beneficial in patients with uncontrolled asthma.
